Back to top
more

BioLife Solutions (BLFS)

(Delayed Data from NSDQ)

$18.03 USD

18.03
374,372

-0.13 (-0.72%)

Updated May 3, 2024 04:00 PM ET

After-Market: $18.03 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (151 out of 252)

Industry: Medical - Products

Better trading starts here.

Zacks News

BioLife Solutions, Inc. (BLFS) Reports Q4 Loss, Tops Revenue Estimates

BioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of -131.25% and 0.06%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

PETQ or BLFS: Which Is the Better Value Stock Right Now?

PETQ vs. BLFS: Which Stock Is the Better Value Option?

Analysts Estimate BioLife Solutions, Inc. (BLFS) to Report a Decline in Earnings: What to Look Out for

BioLife Solutions, Inc. (BLFS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?

Sector ETF report for XHE

BioLife Solutions, Inc. (BLFS) Q2 Earnings and Revenues Top Estimates

BioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of 480.00% and 10.19%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

BioLife Solutions, Inc. (BLFS) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

BioLife Solutions, Inc. (BLFS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Medtronic (MDT) Reports Economic Findings on PRODIGY Data

Medtronic (MDT)-sponsored PRODIGY Trial data was used to analyze cost benefits and outcomes from continuous pulse oximetry and capnography monitoring in high-risk patients.

Company News for May 17, 2021

Companies In The News Are: ACB, NEWR, BLFS, GLOB

BioLife Solutions, Inc. (BLFS) Reports Q1 Loss, Tops Revenue Estimates

BioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of 40.00% and 8.01%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: BioLife Solutions, Inc. (BLFS) Q1 Earnings Expected to Decline

BioLife Solutions, Inc. (BLFS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

HRC or BLFS: Which Is the Better Value Stock Right Now?

HRC vs. BLFS: Which Stock Is the Better Value Option?

HRC vs. BLFS: Which Stock Is the Better Value Option?

HRC vs. BLFS: Which Stock Is the Better Value Option?

BioLife Solutions, Inc. (BLFS) Reports Q4 Loss, Tops Revenue Estimates

BioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of 0.00% and 9.67%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

HRC vs. BLFS: Which Stock Is the Better Value Option?

HRC vs. BLFS: Which Stock Is the Better Value Option?

HRC vs. BLFS: Which Stock Should Value Investors Buy Now?

HRC vs. BLFS: Which Stock Is the Better Value Option?

Trina Mukherjee headshot

3 Soaring MedTech Stocks That Might Lose Ground in 2021

Despite MedTech industry's bright prospects in 2021, investors should be wary of stocks like BLFS, STAA and TGTX, given their unfavorable Zacks Rank and weak fundamentals.

Should You Buy BioLife (BLFS) Ahead of Earnings?

BioLife (BLFS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Moving Average Crossover Alert: BioLife Solutions

BioLife Solutions, Inc. (BLFS) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

BioLife (BLFS) Catches Eye: Stock Jumps 12.1%

BioLife (BLFS) saw a big move last session, as its shares jumped more than 12% on the day, amid huge volumes.

CytoDyn (CYDY) to Report Q4 Earnings: What's in the Cards?

On CytoDyn's (CYDY) upcoming earnings call, investor focus will be on the updates related to its CCR5 antagonist candidate, leronlimab, which is being developed for multiple therapeutic indications.

Why Earnings Season Could Be Great for BioLife Solutions (BLFS)

BioLife Solutions (BLFS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Aurora Cannabis (ACB) to Report Q3 Earnings: What's in Store?

Aurora Cannabis' (ACB) fiscal third-quarter results likely to reflect solid prospects in the Canadian market.